|
KMID : 1177220080110010011
|
|
Korean Journal of Schizophrenia Research
2008 Volume.11 No. 1 p.11 ~ p.19
|
|
|
The Current and Future of Antipsychotic Drugs
|
|
Shim Joo-Cheol
Kong Bo-Geum
Jung Do-Un
Jung Sung-Soo
|
|
|
Abstract
|
|
|
|
Although there are a number of theories regarding the mechanism of action of antipsychotic drug, the precise mechanism remains incompletely understood. Currently approved antipsychotic drugs have at least affinity on dopamine receptors. Serotonin-dopamine receptor antagonism has been considered as the primary mechanism of action of atypical antipsychotics, though “atypicality” of those drugs is not clearly understood yet. There has been an increased interest in developing novel strategies for treating the cognitive deficits in schizophrenia, because those are much better predictors of functional outcome than any other symptom domains. The primary molecular targets for potential drug development for treating cognitive deficit include dopamine receptors in prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, and others. In this article we review the molecular target of currently approved and developing antipsychotic drugs, including drugs for improving cognitive deficit in schizophrenia.
|
|
|
KEYWORD
|
|
|
Schizophrenia, Antipsychotic drug, Mechanism of action
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|